Get the Stockscreener App
1.205
0.02%
-0.0002
Pre-market:
1.17
-0.035
-2.90%
Tharimmune Inc stock is traded at $1.205, with a volume of 6,944.
It is down -0.02% in the last 24 hours and down -21.24% over the past month.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
See More
Previous Close:
$1.2052
Open:
$1.28
24h Volume:
6,944
Relative Volume:
0.10
Market Cap:
$2.38M
Revenue:
-
Net Income/Loss:
$-9.32M
P/E Ratio:
-0.0948
EPS:
-12.7107
Net Cash Flow:
$-7.30M
1W Performance:
+6.65%
1M Performance:
-21.24%
6M Performance:
-39.92%
1Y Performance:
-78.41%
1-Day Range:
$1.205
$1.28
1-Week Range:
$1.05
$1.28
52-Week Range:
$0.952
$6.4485
Tharimmune Inc Stock (THAR) Company Profile
Name
Tharimmune Inc
Sector
Industry
Phone
302-743-2995
Address
1200 ROUTE 22 EAST, BRIDGEWATER
Compare THAR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
THAR
Tharimmune Inc
|
1.205 | 2.38M | 0 | -9.32M | -7.30M | -12.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.47 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
599.76 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
600.51 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.61 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.16 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Tharimmune Inc Stock (THAR) Latest News
Tharimmune (THAR) Expands Board with New Appointment | THAR Stoc - GuruFocus
Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors - standard-journal.com
Healthcare Investment Expert Managing $150M Portfolio Strengthens Tharimmune's Strategic Leadership - Stock Titan
Tharimmune reports data on new biparatopic biologics - BioWorld MedTech
THAR stock touches 52-week low at $1.12 amid sharp annual decline By Investing.com - Investing.com South Africa
THAR stock touches 52-week low at $1.12 amid sharp annual decline - Investing.com Australia
Tharimmune Reports Preclinical Data for Dual-Target Biologics - MarketScreener
Tharimmune Announces Positive Data With Novel Biparatopic PD-1/VEGF & Multispecific HER2/HER3 Biologics Leveraging Proprietary Epiclick(TM) Technology - MarketScreener
Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology - Weatherford Democrat
Breakthrough Cancer Drug Shows Superior Design: Tharimmune's Dual-Target Biologic Outperforms Competition - Stock Titan
Tharimmune receives Nasdaq non-compliance notice - Investing.com Australia
Tharimmune receives Nasdaq non-compliance notice By Investing.com - Investing.com Canada
Tharimmune, Inc. (NASDAQ:THAR) Short Interest Update - Defense World
Virtu Financial LLC Makes New Investment in Tharimmune, Inc. (NASDAQ:THAR) - Defense World
THAR stock touches 52-week low at $1.2 amid sharp annual decline By Investing.com - Investing.com South Africa
Jayud Global Logistics Ltd (JYD): What Makes The Stock Good? - Marketing Sentinel
THAR stock touches 52-week low at $1.2 amid sharp annual decline - Investing.com
Tharimmune Says FDA Requires No Additional Trials of TH104 Against Opioid Exposure - MarketScreener
FDA greenlights Tharimmune’s drug application pathway - Investing.com India
Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure - Eagle-Tribune
FDA Fast-Tracks Tharimmune's Revolutionary Opioid Defense Drug: No Clinical Trials Needed - Stock Titan
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha - Weatherford Democrat
Game-Changing Oral Alternative to Injectable Antibody Achieves Key Milestone - Stock Titan
Tharimmune leverages Epiclick platform to expand pipeline - BioWorld Online
Hillstream Biopharma stock hits 52-week low at $1.36 - Investing.com
Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology - Markets Insider
Tharimmune unveils novel cancer treatment HS1940 - Investing.com India
Tharimmune unveils novel cancer treatment HS1940 By Investing.com - Investing.com South Africa
Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Declines By 58.6% - Defense World
Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Expands By 148.7% - Defense World
Tharimmune appoints new CFO following resignation By Investing.com - Investing.com Canada
Tharimmune Says Thomas Hess Resigns As CFO -February 27, 2025 at 05:34 pm EST - Marketscreener.com
Tharimmune Says Thomas Hess Resigns As CFO - TradingView
Tharimmune appoints new CFO following resignation - Investing.com
Hillstream Biopharma stock hits 52-week low at $1.83 By Investing.com - Investing.com Canada
Hillstream Biopharma stock hits 52-week low at $1.83 - Investing.com
Financial Analysis: ObsEva (NASDAQ:OBSV) & Tharimmune (NASDAQ:THAR) - Defense World
Comparing Tharimmune (NASDAQ:THAR) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Tharimmune (NASDAQ:THAR) and Cara Therapeutics (NASDAQ:CARA) Head-To-Head Review - Armenian Reporter
Comparing Cara Therapeutics (NASDAQ:CARA) & Tharimmune (NASDAQ:THAR) - Defense World
Larchmont broker accused of years-long insider trading scheme - Westfair Communications
Tharimmune (NASDAQ:THAR) Trading 3% Higher – Should You Buy? - Defense World
Tharimmune to Present at the Microcap Conference 2025 - Bellingham Herald
Tharimmune Inc Stock (THAR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.04%
2.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):